Drug Patents owned by Handa

1. List of Tascenso Odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10555902 HANDA Stable fingolimod dosage forms
Jan, 2036

(12 years from now)

US9925138 HANDA Stable solid fingolimod dosage forms
Jan, 2036

(12 years from now)

US10925829 HANDA Stable solid fingolimod dosage forms
Jan, 2036

(12 years from now)

Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient

Market Authorisation Date: 23 December, 2021

Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

TASCENSO ODT family patents

7

United States

1

Taiwan, Province of China

1

Japan

1

Australia

1

Canada

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in